Growth factor receptor expression in orbital lymphangioma: possible therapeutic implications.
OBJECTIVE
To examine the expression of molecules targeted by imatinib mesylate (STI571;Gleevec) and epidermal growth factor receptor (EGFR) inhibitors in orbital lymphangiomas.


METHODS
Retrospective observational case series.


METHODS
Six patients with orbital lymphangioma treated at four institutions between March 2000 and December 2002.


METHODS
Tissue specimens and medical records from six patients were collected. Immunohistochemical analysis was performed using antibodies against c-kit and platelet-derived growth factor receptor (PDGFR) alpha and beta and EGFR tyrosine kinase.
Esmaeli
Bita
B
Ophthalmology Section, Department of Plastic Surgery, University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030-4009, USA. besmaeli@mdanderson.org
Prieto
Victor G
VG
Gonnering
Russell
R
Hawes
Michael J
MJ
Diba
Roxana
R
Saadati
Hossein G
HG
Shepler
Todd R
TR
Karcioglu
Zeynel
Z
D000293:Adolescent; D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use; D004730:Endothelium, Vascular / Q000378:metabolism*; D066246:ErbB Receptors / Q000378:metabolism; D005260:Female; D006133:Growth Substances / Q000378:metabolism*; D006801:Humans; D007150:Immunohistochemistry; D008202:Lymphangioma / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009131:Muscle, Smooth, Vascular / Q000378:metabolism*; D009918:Orbital Neoplasms / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D019009:Proto-Oncogene Proteins c-kit / Q000378:metabolism; D020796:Receptor, Platelet-Derived Growth Factor alpha / Q000378:metabolism; D020797:Receptor, Platelet-Derived Growth Factor beta / Q000378:metabolism; D012189:Retrospective Studies
D000970:Antineoplastic Agents; D006133:Growth Substances; D066246:ErbB Receptors; D019009:Proto-Oncogene Proteins c-kit; D020796:Receptor, Platelet-Derived Growth Factor alpha; D020797:Receptor, Platelet-Derived Growth Factor beta